BRIEF—Tasly biotech unit in billion dollar Hong Kong listing

Reuters reports that Shanghai-listed Tasly Pharmaceutical plans to list its biotech unit in Hong Kong, a floatation that would likely raise up to a billion dollars.

The firm, which has a significant interest in traditional Chinese medicines, also develops prescription medications and sells Pro-UK, a class-I biologic clot buster.

Founded in 2001, the firm has about ten other candidates in its pipeline.